The effects of dihydro‐CDDO‐trifluoroethyl amide (dh404), a rodent‐tolerable bardoxolone methyl analog, on the tubulointerstitium, were tested in an Institute of Cancer Research‐derived glomerulonephritis (ICGN) mouse model of kidney disease. The effect of dh404 on mitochondrial function, was assessed using human proximal tubular cells in vitro.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.